Lyophilized preparation, lyophilized solution, methods for producing same, and liquid agent
The lyophilized preparation with solubilizing agents improves the solubility and stability of the calpain activity probe, addressing solubility and stability issues, enabling effective diagnostic solutions for calpain-related diseases.
Patent Information
- Application Number
- PCT/JP2024/016753
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-12
- Filing Date
- 2024-05-01
- Publication Date
- 2024-11-21
AI Technical Summary
The existing probe for detecting calpain activity has low water solubility and stability issues, making it unsuitable for clinical use and difficult to achieve the desired concentration for effective diagnostics.
A lyophilized preparation containing the probe, combined with solubilizing agents like polysorbate and antioxidants, is developed to enhance solubility and stability, allowing for improved re-dissolution in water and prolonged purity.
The lyophilized formulation effectively stabilizes the probe's content and purity, enabling the preparation of a dosage solution at a practical concentration, suitable for clinical use in diagnosing calpain-related diseases.
Smart Images

Figure JP2024016753_21112024_PF_FP_ABST
Abstract
Description
Freeze-dried preparation, freeze-dried solution, and methods for producing the same, and liquid preparation
[0001] The present invention relates to a freeze-dried preparation, a freeze-dried solution, methods for producing these, and a liquid preparation.
[0002] Calpain is a Ca 2+ Calpains are cysteine proteases that are activated by a specific ATP-dependent pathway and act as modulators of the function and structure of substrate proteins by limited cleavage. While calpains are involved in a variety of biological phenomena, their activity and pathogenic mutations in their genes have been reported to be associated with a variety of diseases, including neurodegenerative disorders, cardiomyopathy, ischemic diseases, cancer, and eye diseases. Furthermore, calpains are essential for the survival and infection of pathogens in some infectious diseases, such as malaria, trypanosomiasis, and schistosomiasis. Therefore, visualizing calpain activity is important for the diagnosis of calpain-related diseases, analysis of disease mechanisms, and drug discovery research.
[0003] Fluorescence imaging is a useful method for detecting calpain activity in real time. For example, a probe in which a peptide is bound to the fluorescent dye Hydroxymethyl Rhodamine Green (HMRG) has been reported as a method for detecting calpain activity in living cells without relying on gene transfer (Patent Document 1).
[0004] WO2022 / 270607
[0005] When the probe described in Patent Document 1 is used for the diagnosis of calpain-related diseases, it is expected that an aqueous solution of the probe is prepared, and the aqueous solution is brought into contact with the affected area via an administration route such as injection or spray, followed by fluorescent imaging of calpain activity. However, as the inventors further investigated practical applications, they found that the probe described in Patent Document 1 has low solubility in water and cannot be dissolved in water instantly, making it difficult to provide an administration solution containing the probe at a desired concentration for clinical use. They also found that the aqueous solution of the probe leaves room for improvement in terms of the stability of its content and purity.
[0006] The present invention has been made to solve the above-mentioned problems, and a main object of the present invention is to provide a formulation that can prepare an administration solution containing the above-mentioned probe at a practical concentration and that has excellent stability in the content and purity of the probe.
[0007] [1] According to one aspect of the present invention, a compound represented by the following general formula (I): [wherein A and B each independently represent the same or different amino acid residues, wherein the bond between A and the NH bonded to A is an amide bond between the C-terminus of A and the NH, A and B are bonded by an amide bond, and the bond between B and the carbonyl (C═O) bonded to B is an amide bond between the N-terminus of B and the carbonyl (C═O); R 1 are the same or different and represent substituents attached to the benzene ring; p represents an integer of 0 to 4; R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 each independently represents a hydrogen atom, a hydroxyl group (OH group), a halogen atom, or an optionally substituted linear, branched, or cyclic alkyl group; R 8 and R 9 each independently represents a hydrogen atom or an optionally substituted linear, branched, or cyclic alkyl group, or R 8 and R 9 may be bonded to form a ring, or R 3 and R 8 may be bonded to form a ring, and / or R 4 and R 9 may be bonded to form a ring; X represents a linear or branched C1-C3 alkylene group; R 10 and R 11 each independently represents a hydrogen atom, a hydroxyl group (OH), an alkoxy group, or an optionally substituted linear, branched, or cyclic alkyl group, or R 10 and R 11 may be bonded to form a ring; 12represents a hydrogen atom, an optionally substituted linear, branched, or cyclic alkyl group, an optionally substituted linear or branched alkenyl group, an optionally substituted linear or branched alkynyl group, an optionally substituted aryl group, or an optionally substituted heterocyclic group, or R 10 or R 11 L may be bonded to form a ring; L is an amide bond, an ester bond, or -(linear or branched alkylene-O-) n- (n represents an integer of 1 to 10) or a single bond.] or a salt thereof. [2] The freeze-dried formulation according to [1] above may further comprise a solubilizing agent. [3] In the freeze-dried formulation according to [2] above, the solubilizing agent may comprise polyoxyethylene sorbitan fatty acid esters and / or polyoxyethylene polyoxypropylene glycol. [4] In the freeze-dried formulation according to [2] or [3] above, the solubilizing agent may be at least one selected from polysorbate 20, polysorbate 40, and polysorbate 80. [5] In the freeze-dried formulation according to [2] or [3] above, the content of the solubilizing agent may be 3 to 300 parts by weight per part by weight of the compound or a salt thereof. [6] The freeze-dried formulation according to any of [1] to [5] above may further comprise an antioxidant. [7] In the freeze-dried formulation according to [6] above, the antioxidant may comprise methionine. [8] In the freeze-dried formulation according to [6] or [7] above, the content of the antioxidant may be 0.01 to 100 parts by weight per part by weight of the compound or its salt. [9] The freeze-dried formulation according to any one of [1] to [8] above may further comprise at least one additive selected from a pH adjuster, an excipient, and an isotonicity agent.
[10] The freeze-dried formulation according to any one of [1] to [9] above may be a diagnostic agent for glaucoma or cancer.
[11] According to another aspect of the present invention, there is provided a freeze-dried solution comprising the compound represented by general formula (I) or a salt thereof, a solubilizing agent, and water.
[12] In the freeze-dried solution according to
[11] above, the solubilizing agent may comprise polyoxyethylene sorbitan fatty acid esters and / or polyoxyethylene polyoxypropylene glycol.
[13] In the freeze-dried solution according to
[11] or
[12] above, the solubilizing agent may be at least one selected from polysorbate 20, polysorbate 40, and polysorbate 80.
[14] The freeze-dried solution according to any one of
[11] to
[13] above may further contain an antioxidant.
[15] In the freeze-dried solution according to
[14] above, the antioxidant may contain methionine.
[16] In the freeze-dried solution according to any one of
[11] to
[15] above, the concentration of the compound or a salt thereof may be 6 μM or more.
[17] The freeze-dried solution according to any one of
[11] to
[16] above may further contain at least one additive selected from a pH adjuster, an excipient, and an isotonicity agent.
[18] According to another aspect of the present invention, there is provided a method for producing the freeze-dried solution according to any one of
[11] to
[17] above, the method comprising mixing the compound or a salt thereof with a solubilizing agent or an aqueous solution thereof to prepare a concentrated solution, and mixing the concentrated solution with a diluent.
[19] In the method for producing the freeze-dried solution according to
[18] above, the concentration of the solubilizing agent in the concentrated solution may be 5 wt% or more.
[20] In the method for producing the freeze-dried solution according to
[18] or
[19] above, the concentrated solution and / or the diluent may contain an antioxidant.
[21] The method for producing the lyophilized solution according to any one of
[18] to
[20] above may further comprise deoxygenating the solubilizing agent or its aqueous solution, the concentrated solution, and / or the diluent.
[22] According to another aspect of the present invention, there is provided a method for producing a lyophilized formulation, comprising lyophilizing the lyophilized solution according to any one of
[11] to
[17] above.
[23] According to another aspect of the present invention, there is provided a liquid preparation obtained by reconstituting the lyophilized formulation according to any one of [1] to
[10] above.
[0008] According to an embodiment of the present invention, the probe is freeze-dried to improve its solubility in water and stabilize its content and purity. Preferably, the probe is freeze-dried together with a solubilizing agent.
[0009] 1 is a graph showing the results of a dissolution test of Compound A.
[0010] Preferred embodiments of the present invention will be described below, but the present invention is not limited to these embodiments. In this specification, the term "to" indicating a range of values includes the upper and lower limits.
[0011] A. Freeze-dried Preparations A freeze-dried preparation according to an embodiment of the present invention comprises a compound represented by the above general formula (I) (hereinafter, may be referred to as "compound (I)") or a salt thereof. Compound (I) or a salt thereof in powder form has low solubility in water, but a freeze-dried preparation comprising compound (I) or a salt thereof can have excellent resolubility in water or physiological saline. Furthermore, by forming the freeze-dried preparation, the generation of oxidants and the like is suppressed compared to the case of a liquid preparation, thereby improving the stability of purity. A freeze-dried preparation according to an embodiment of the present invention preferably further comprises a solubilizing agent.
[0012] A-1. Compound represented by formula (I) In the above formula (I), R 1 represents a substituent bonded to the benzene ring. p is an integer of 0 to 4, and may be 0 to 3, 0 to 2, 0 to 1, 1, or 0. R 1 Examples of R include, but are not limited to, an optionally substituted linear or branched alkyl group; an optionally substituted linear or branched alkoxy group; a halogen atom; an optionally substituted amino group; a substituted silyl group; or an acyl group. 1 may be the same or different.
[0013] R 8 and R 9 When R 3 and R 8 When R 4 and R 9 When R 10 and R 11 When R and R are bonded to form a ring, the ring may contain a heteroatom (such as an oxygen atom, a nitrogen atom, or a sulfur atom), and may be, for example, a cycloalkyl or a cyclic ether. 12 and R 10 or R 11 When they combine to form a ring, the ring may be a cyclic ether, and these rings may be 3 to 14 members, 3 to 10 members, 3 to 8 members, or 3 to 6 members.
[0014] Throughout this specification, substituents on alkyl groups or alkyl moieties of other groups can include halogen atoms, hydroxyl groups, amino groups, alkylamino groups, dialkylamino groups, thiol groups, alkylthiol groups, sulfonyl groups, alkylsulfonyl groups, alkoxy groups, cyclic ethers, carboxyl groups, alkylcarbonyl groups, alkoxycarbonyl groups, alkoxycarbonylamino groups, alkylcarbonyloxy groups, alkylaminocarbonyl groups, alkylcarbonylamino groups, carbonylamino groups, and hydrazinyl groups. When an alkyl group is substituted, the number of substituents can be, for example, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2, 1, 2, or 3.
[0015] The substituents on the amino group may be linear or branched alkyl groups which may be substituted, and when the amino group is substituted, the number of the substituents may be 1 to 2, 1, or 2.
[0016] The substituents of the substituted silyl group may be an optionally substituted linear or branched alkyl group or an optionally substituted phenyl group. The number of substituents of the silyl group may be, for example, 1 to 4, 1 to 3, 1 to 2, 1, 2, 3, or 4.
[0017] In general formula (I), the amino acid may be a naturally occurring amino acid or a derivative thereof, such as a stereoisomer of a natural amino acid, as long as it is an amino acid that is cleaved by calpain. Examples of the amino acid include Met, Ser, Ala, Thr, Val, Tyr, Leu, Asn, Ile, Gln, Pro, Asp, Phe, Glu, Trp, Lys, Cys, Arg, Gly, His (all of which are expressed by three-letter amino acid code), norleucine (Nle), and methionine sulfoxide (MetO).
[0018] As used herein, the term "alkyl group" or the "alkyl" moiety in other groups refers to a linear, branched, or cyclic saturated hydrocarbon group, preferably a saturated hydrocarbon group having 1 to 6 carbon atoms, such as a methyl group, ethyl group, n-propyl group, i-propyl group, n-butyl group, sec-butyl group, t-butyl group, isobutyl group, pentyl group, isopentyl group, 2,3-dimethylpropyl group, hexyl group, cyclopropyl group, cyclobutyl group, cyclopentyl group, and cyclohexyl group; more preferably a C1-5 alkyl group, such as a methyl group, ethyl group, n-propyl group, i-propyl group, n-butyl group, sec-butyl group, t-butyl group, isobutyl group, pentyl group, isopentyl group, or 2,3-dimethylpropyl group; even more preferably a C1-3 alkyl group, such as a methyl group, ethyl group, n-propyl group, or i-propyl group; and most preferably a methyl group or an ethyl group. Furthermore, the term "alkylene group" refers to a divalent group obtained by removing one hydrogen atom from the above alkyl group.
[0019] The "alkoxy group" refers to a group bonded to the above-mentioned alkyl group via an oxygen atom ((alkyl)-O- group), and the alkyl group portion is as defined above. For example, the alkoxy group may have an alkyl group portion having 1 to 6 carbon atoms. Examples of the alkoxy group include a methoxy group, an ethoxy group, a 1-propyloxy group, a 2-propyloxy group, a 2-methyl-1-propyloxy group, a 2-methyl-2-propyloxy group, a 2,2-dimethyl-1-propyloxy group, a 1-butyloxy group, a 2-butyloxy group, a 2-methyl-1-butyloxy group, a 3-methyl-1-butyloxy group, a 2-methyl-2-butyloxy group, a 3-methyl-2-butyloxy group, a 1-pentyloxy group, a 2-pentyloxy group, a 3-pentyloxy group, a 2-methyl-1-pentyloxy group, a 3-methyl-1-pentyloxy group, a 2-methyl-2-pentyloxy group, a 3-methyl-2-pentyloxy group, a 1-hexyloxy group, a 2-hexyloxy group, and a 3-hexyloxy group. The C1-6 alkoxy group is preferably a C1-5 alkoxy group, and more preferably a methoxy group, an ethoxy group, an n-propyloxy group, an i-propyloxy group, an n-butyloxy group, a sec-butyloxy group, a t-butyloxy group, an isobutyloxy group, a pentyloxy group, an isopentyloxy group, or a 2,3-dimethylpropyloxy group.
[0020] An "alkenyl group" is a monovalent group obtained by removing one hydrogen atom from any carbon atom of a straight-chain, branched, or cyclic unsaturated hydrocarbon having one or more carbon-carbon double bonds, and may have, for example, 2 to 10, 2 to 6, or 2 to 4 carbon atoms. Examples of C2-10 alkenyl groups include vinyl, propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 1-methyl-2-butenyl, 1-methyl-3-butenyl, 1-methylidenebutyl, 2-methyl-1-butenyl, 2- Methyl-2-butenyl group, 2-methyl-3-butenyl group, 2-methylidenebutyl group, 3-methyl-1-butenyl group, 3-methyl-2-butenyl group, 3-methyl-3-butenyl group, 1-ethyl-1-propenyl group, 1-ethyl-2-propenyl group, 1-hexenyl group, 2-hexenyl group, 3-hexenyl group, 4-hexenyl group, 5-hexenyl group, 1-methyl-1-pentenyl group, 1- Methyl-2-pentenyl group, 1-methyl-3-pentenyl group, 1-methyl-4-pentenyl group, 1-methylidenepentyl group, 2-methyl-1-pentenyl group, 2-methyl-2-pentenyl group, 2-methyl-3-pentenyl group, 2-methyl-4-pentenyl group, 2-methylidenepentyl group, 3-methyl-1-pentenyl group, 3-methyl-2-pentenyl group, 3-methyl-3-pentenyl group Examples of such groups include 3-methyl-4-pentenyl, 3-methylidenepentyl, 4-methyl-1-pentenyl, 4-methyl-2-pentenyl, 4-methyl-3-pentenyl, 4-methyl-4-pentenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, octenyl, nonenyl, and decenyl groups.
[0021] An "alkynyl group" is a monovalent group obtained by removing one hydrogen atom from any carbon atom of a straight-chain or branched unsaturated hydrocarbon having one or more carbon-carbon triple bonds, and may have, for example, 2 to 6 or 2 to 4 carbon atoms. Examples of the alkynyl group include an ethynyl group, a 1-propynyl group, a 2-propynyl group, a 1-butynyl group, a 2-butynyl group, a 3-butynyl group, a pentynyl group, a hexynyl group, and a phenylethynyl group.
[0022] An "acyl group" has the same meaning as an alkanoyl group and is a group represented by R-C(=O)-. The R portion in an acyl group represented by this structure includes a hydrogen atom, an optionally substituted linear or branched alkyl group, or an optionally substituted aryl group. For example, the acyl group may have 2 to 7 carbon atoms and includes an acetyl group, a propionyl group, a butyryl group, an isobutyryl group, a valeryl group, an isovaleryl group, a pivaloyl group, a valeryl group, an isovaleryl group, a hexanoyl group, and a heptanoyl group.
[0023] An "aryl group" is a monovalent aromatic hydrocarbon group which may have, for example, 6 to 10 carbon atoms and includes phenyl and naphthyl groups.
[0024] A "heterocyclic group" is a monovalent group containing at least one heteroatom selected from a nitrogen atom, an oxygen atom, and a sulfur atom, and is preferably 5 to 14 members. The heterocyclic group may be a monocyclic heterocyclic group or a fused heterocyclic group. The number of heteroatoms contained in a 5 to 14-membered heterocyclic group may be, for example, 1 to 5, 1 to 4, 1 to 3, 1 to 2, 2, or 1. For example, various combinations exist, such as a heterocyclic group containing one nitrogen atom, a heterocyclic group containing two nitrogen atoms, a heterocyclic group containing three nitrogen atoms, a heterocyclic group containing one oxygen atom, a heterocyclic group containing two oxygen atoms, a heterocyclic group containing one oxygen atom and one nitrogen atom, and a heterocyclic group containing one sulfur atom. The 5 to 14-membered heterocyclic group may be aromatic or non-aromatic. The monocyclic heterocyclic group is preferably a 5- or 6-membered ring. The fused heterocyclic group is preferably an 8- to 10-membered ring.Examples of 5- to 14-membered heterocyclic groups include piperidyl, piperazyl, morpholyl, quinuclidyl, pyrrolidinyl, azetidyl, oxetyl, azetidin-2-one-yl, aziridinyl, tropanyl, furyl, tetrahydrofuryl, thienyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, dioxolanyl, oxazolyl, oxazolinyl, isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, imidazolyl, imidazolinyl, and imidazo. Rizinyl, oxazolidinyl, thiazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, oxadiazolyl, furazanyl, thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, pyranyl, pyridyl, piperidinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, dioxanyl, oxazinyl, morpholinyl, thiazinyl, triazinyl, benzofuranyl, isobenzofuranyl, dihydrido Isobenzofuranyl, dihydroisobenzofuranyl, benzothienyl, isobenzothienyl, dihydrobenzothienyl, dihydroisobenzothienyl, tetrahydrobenzothienyl, quinolyl, isoquinolyl, quinazolinyl, phthalazinyl, pteridinyl, coumaryl, chromonyl, 1,4-benzodiazepinyl, indolyl, isoindolyl, benzimidazoyl, benzofuryl, purinyl, acridinyl, phenoxazinyl, phenothiazinyl Examples of the alkyl group include benzoxazolyl, benzothiazolyl, indazolyl, benzimidazolyl, benzodioxolanyl, benzodioxanylchromenyl, chromanyl, isochromanyl, chromanonyl, cinnolinyl, quinoxalinyl, indolizinyl, quinolidinyl, imidazopyridyl, naphthyridinyl, dihydrobenzoxazinyl, dihydrobenzoxazolinonyl, dihydrobenzoxazinonyl, and benzothioxanyl.
[0025] As used herein, the term "halogen atom" refers to a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom, and is preferably a fluorine atom, a chlorine atom, or a bromine atom, and more preferably a fluorine atom or a chlorine atom. As used herein, the term "carboxyl group" refers to a group represented by -C(=O)-OH.
[0026] Preferred amino acid A is Met, Thr, His, Tyr, Phe, Ser, Gln, Arg, Lys, MetO, and Nle. Preferred amino acid B is a hydrophobic amino acid such as Leu or Val, more preferably Leu. Preferred combinations of (amino acid B) and (amino acid A) include Leu-Met, Leu-Nle, Leu-Phe, Leu-Tyr, Leu-Thr, Leu-Arg, Leu-Lys, Leu-His, Val-Tyr, Val-Met, and Leu-Ser.
[0027] R 1 is preferably a linear or branched alkyl group. Also, p is preferably 0 or 1, more preferably 0.
[0028] R 2 is preferably a hydrogen atom.
[0029] R 3 is preferably a hydrogen atom.
[0030] R 4 is preferably a hydrogen atom.
[0031] R 5 is preferably a hydrogen atom.
[0032] R 6 is preferably a hydrogen atom.
[0033] R 7 is preferably a hydrogen atom.
[0034] R 8 is preferably a hydrogen atom.
[0035] R 9 is preferably a hydrogen atom.
[0036] R 10 is preferably a hydrogen atom, an alkyl group or an alkoxy group, and more preferably a hydrogen atom, a methyl group or a methoxy group.
[0037] R 11is preferably a hydrogen atom, an alkyl group or an alkoxy group, and more preferably a hydrogen atom, a methyl group or a methoxy group.
[0038] Or, R 10 and R 11 are preferably bonded to each other to form a cycloalkyl group, more preferably a C3-C5 cycloalkyl group.
[0039] R 12 is preferably a hydrogen atom or an optionally substituted linear, branched, or cyclic alkyl group, more preferably a hydrogen atom or a linear, branched, or cyclic alkyl group having 1 to 6 carbon atoms which may be substituted with one or more groups selected from a hydroxyl group, a carboxyl group, a cycloether, an alkoxy group (e.g., a methoxy group, an ethoxy group), a sulfonyl group, a halogen atom, an amino group, a methylamino group, and a dimethylamino group, and even more preferably a hydrogen atom or a linear or branched alkyl group having 1 to 4 carbon atoms which may be substituted with one or more groups selected from a hydroxyl group, a carboxyl group, a cycloether, an alkoxy group (e.g., a methoxy group, an ethoxy group), a sulfonyl group, a halogen atom, an amino group, a methylamino group, and a dimethylamino group (e.g., a methyl group, an ethyl group, a propyl group, an isopropyl group, a t-butyl group). Alternatively, R 12 is preferably R 10 or R 11 and combine with each other to form a 3- to 8-membered heterocyclic group containing 1 or 2 oxygen atoms (eg, dioxolanyl, dioxanyl).
[0040] L is preferably -(linear or branched alkylene-O-) n - (n is an integer of 1 to 10) or a single bond. The straight-chain or branched alkylene may be, for example, an alkylene having 1 to 4 carbon atoms, preferably 2 or 3 carbon atoms, and more preferably 2 carbon atoms.
[0041] For example, in the above formula (I), -OL-R 12 The group represented by the formula (II) may be a group represented by the formula (II) below.
[0042] [In the formula, n represents an integer of 0 to 10.]
[0043] Furthermore, for example, in the above formula (I), -OL-R 12 The group represented by the formula (I) may be a hydroxyl group or a group selected from the following:
[0044]
[0045] Furthermore, for example, in the above formula (I),
[0046] The partial structure represented by the formula (wherein m is an integer of 1 to 3, and q is 0 or 1) may be a structure represented by the formula (wherein m is an integer of 1 to 3, and q is 0 or 1).
[0047]
[0048] A preferred example of compound (I) is a compound of formula (III): In addition, compounds of formula (III) in which the combination of amino acids is appropriately changed are also preferred examples of compound (I).
[0049] The salt of compound (I) may be any pharmaceutically acceptable salt, and examples thereof include base addition salts, acid addition salts, amino acid salts, etc. Examples of the base addition salt include metal salts such as lithium salt, sodium salt, potassium salt, calcium salt, magnesium salt, etc.; organic amine salts such as ammonium salt, methylamine salt, dimethylamine salt, dicyclohexylamine salt, tris(hydroxymethyl)aminomethane salt, N,N-bis(hydroxyethyl)piperazine salt, 2-amino-2-methyl-1-propanol salt, ethanolamine salt, N-methylglucamine salt, L-glucamine salt, triethylamine salt, piperidine salt, morpholine salt, etc.; or salts with basic amino acids such as lysine, δ-hydroxylysine, arginine, etc. Examples of acid addition salts include mineral acid salts such as hydrochloride, hydrobromide, sulfate, nitrate, and phosphate, and organic acid salts such as methanesulfonate, benzenesulfonate, paratoluenesulfonate, citrate, oxalate, acetate, propionate, tartrate, fumarate, maleate, malate, succinate, benzoate, mandelate, cinnamate, lactate, glycolate, glucuronate, ascorbate, nicotinate, salicylate, and trifluoroacetate. Examples of amino acid salts include glycine salts. However, the salts of compound (I) are not limited to these.
[0050] Compound (I) may have one or more asymmetric carbon atoms depending on the type of substituent, and may exist as stereoisomers such as optical isomers or diastereoisomers. Pure stereoisomers, any mixture of stereoisomers, racemates, etc. are all encompassed within the scope of the present invention. Furthermore, the compound represented by general formula (I) or a salt thereof may exist as a hydrate or solvate, and all of these substances are encompassed within the scope of the present invention. The type of solvent that forms the solvate is not particularly limited, and examples include solvents such as ethanol, acetone, and isopropanol. In this specification, a reference to "Compound (I)" includes any mixture of isomers or a specific stereoisomer of Compound (I), pharmacologically acceptable salts, hydrates, and solvates of Compound (I), as well as hydrates or solvates of pharmacologically acceptable salts of Compound (I), even if not explicitly stated, unless clearly incompatible.
[0051] The content of compound (I) in the lyophilized preparation may be any amount that will give a liquid preparation containing compound (I) at a desired concentration upon reconstitution, and can be appropriately set by adjusting the amounts of solubilizing agents, excipients, etc. added.
[0052] A-2. Solubilizing Agent The solubilizing agent can contribute to improving the solubility of Compound (I). As the solubilizing agent, for example, a surfactant can be used. Specifically, the solubilizing agent may be an anionic surfactant, a cationic surfactant, or a nonionic surfactant, and is preferably a nonionic surfactant.
[0053] The HLB of the solubilizing agent is, for example, 9 or more, preferably 13 or more, more preferably 16 or more, and may be, for example, 19 or less, or, for example, 18 or less. By using a solubilizing agent having the above HLB, the effect of improving the solubility of compound (I) can be more suitably obtained.
[0054] Specific examples of solubilizing agents include polyoxyethylene sorbitan fatty acid esters, specifically polysorbate 20 (HLB: 16.7), polysorbate 21 (HLB: 13.3), polysorbate 40 (HLB: 15.6), polysorbate 60 (HLB: 14.9), polysorbate 61 (HLB: 9.6), polysorbate 65 (HLB: 10.5), polysorbate 80 (HLB: 15.0), polysorbate 81 (HLB: 10.0), and polysorbate 85 (HLB: 11.0). Among these, polysorbate 20, polysorbate 40, and polysorbate 80 are preferred, with polysorbate 20 and polysorbate 80 being more preferred. Polyoxyethylene polyoxypropylene glycol is also a preferred example. The solubilizing agent may be used alone or in combination of two or more.
[0055] The content of the solubilizing agent in the lyophilized formulation is, for example, 3 to 300 parts by weight, preferably 10 to 100 parts by weight, and more preferably 20 to 50 parts by weight, relative to 1 part by weight of Compound (I). When two or more solubilizing agents are used in combination, the above content refers to the total content of the solubilizing agents. The same applies to the contents of other components.
[0056] A-3. Additives The lyophilized formulation may further contain any appropriate pharmaceutically acceptable additive depending on the purpose. Examples of such additives include antioxidants, pH adjusters, excipients, isotonicity agents, etc.
[0057] The antioxidant is not limited as long as the effects of the present invention can be obtained, and preferred examples include methionine, ascorbic acid, tocopherol, cysteine, thioglycerin, etc. Among these, methionine and cysteine are preferred. One type of antioxidant may be used alone, or two or more types may be used in combination. When the lyophilized preparation contains an antioxidant, the content of the antioxidant in the lyophilized preparation is, for example, 0.01 to 100 parts by weight, preferably 0.1 to 50 parts by weight, and more preferably 0.25 to 25 parts by weight, per part by weight of Compound (I).
[0058] The pH adjuster is not limited as long as the effects of the present invention can be obtained, and examples thereof include hydrochloric acid, sodium hydroxide, phosphoric acid, phosphate (Na 3 P.O. 4 , Na 2 HPO 4 , NaH 2 P.O. 4 , K.H. 2 P.O. 4 etc.), carbonic acid, carbonate (Na 2 CO 3 , NaHCO 3 etc.), acetic acid, acetate (CH 3 Preferred examples of the pH adjuster include sodium citrate (COONa, etc.), citric acid, citrate salts (trisodium citrate, etc.), HEPES, etc. One pH adjuster may be used alone, or two or more pH adjusters may be used in combination. The pH adjuster may constitute a buffer. The pH adjuster may be contained in the freeze-dried preparation so that the pH becomes, for example, 6 to 8 when the freeze-dried preparation is dissolved in physiological saline or water for injection.
[0059] The excipient is not limited as long as the effects of the present invention can be obtained, and preferred examples include monosaccharides such as glucose, disaccharides such as sucrose, trehalose, maltose, and lactose, and sugar alcohols such as mannitol and sorbitol. Among these, trehalose and sucrose are preferred. One type of excipient may be used alone, or two or more types may be used in combination. When the lyophilized formulation contains an excipient, the content of the excipient in the lyophilized formulation is, for example, 1 to 25,000 parts by weight, preferably 10 to 10,000 parts by weight, and more preferably 100 to 5,000 parts by weight, per part by weight of compound (I).
[0060] The isotonicity agent is not limited as long as the effects of the present invention can be obtained, and preferred examples include sodium chloride, potassium chloride, etc. One type of isotonicity agent may be used alone, or two or more types may be used in combination. The isotonicity agent may be added to the lyophilized preparation so that the osmotic pressure ratio to physiological saline becomes 0.8 to 1.2 when the lyophilized preparation is dissolved in a solvent to prepare an administration solution of a predetermined concentration.
[0061] B. Freeze-Dried Solution According to another aspect of the present invention, a freeze-dried solution is provided comprising Compound (I), a solubilizing agent, and water. The freeze-dried solution according to this embodiment of the present invention preferably further comprises an antioxidant, and may contain any other appropriate additives as needed. The solubilizing agent, antioxidant, and other additives are as described in Section A. Preferred examples of water include water for injection, purified water, and sterilized purified water. The freeze-dried formulation described in Section A can be suitably obtained by freeze-drying the freeze-dried solution according to this embodiment of the present invention.
[0062] The concentration of Compound (I) in the lyophilized solution is, for example, 6 μM or more, preferably 60 μM or more, more preferably 120 μM or more, and even more preferably 240 μM or more, and is, for example, 10 mM or less, and for example, 1 mM or less.
[0063] The concentration of the solubilizing agent in the lyophilized solution is, for example, 0.05 mg / mL to 50 mg / mL, preferably 1 mg / mL to 20 mg / mL, and more preferably 2 mg / mL to 10 mg / mL. A lyophilized solution containing the solubilizing agent at the above concentration can stably dissolve Compound (I) at a high concentration. Furthermore, a lyophilized preparation produced from a lyophilized solution containing the solubilizing agent at the above concentration can be easily dissolved in a dissolving solution.
[0064] When the lyophilized solution contains an antioxidant, the concentration of the antioxidant in the lyophilized solution is, for example, 0.001 mg / mL to 10 mg / mL, preferably 0.01 mg / mL to 5 mg / mL, more preferably 0.02 mg / mL to 1 mg / mL. In a lyophilized solution containing an antioxidant at the above concentrations, denaturation (e.g., oxidation) of Compound (I) can be suppressed, and therefore a decrease in purity can be suppressed.
[0065] When the freeze-drying solution contains a pH adjuster, the concentration of the pH adjuster in the freeze-drying solution is not limited as long as the effects of the present invention are obtained. When the pH adjuster is a phosphate (for example, a phosphate buffer), the concentration is, for example, 1 mM to 500 mM, preferably 2 mM to 300 mM, and more preferably 3 mM to 150 mM.
[0066] When the lyophilized solution contains an excipient, the concentration of the excipient in the lyophilized solution is, for example, 1 mg / mL to 400 mg / mL, preferably 5 mg / mL to 200 mg / mL, and more preferably 10 mg / mL to 100 mg / mL. A lyophilized solution containing an excipient at the above concentrations can suitably produce a lyophilized preparation that is easy to handle.
[0067] C. Method for Producing a Freeze-Dried Solution According to another aspect of the present invention, a method for producing a freeze-dried solution is provided. A method for producing a freeze-dried solution according to an embodiment of the present invention includes: (Step I) mixing compound (I) with a solubilizing agent or an aqueous solution thereof to prepare a concentrated solution; and (Step II) mixing the concentrated solution with a diluent. According to this production method, a concentrated solution containing compound (I) at a high concentration can be obtained by dissolving compound (I) in the presence of a solubilizing agent, and a freeze-dried solution containing compound (I) at a desired concentration can be obtained by diluting the concentrated solution. Therefore, according to this production method, the freeze-dried solution described in Section B can be suitably produced. The production method can further include deoxidizing the solubilizing agent or an aqueous solution thereof, the concentrated solution, and / or the diluent.
[0068] C-1. Step I In Step I, compound (I) is mixed with a solubilizing agent or an aqueous solution thereof to prepare a concentrated solution. Compound (I) and the solubilizing agent may be mixed directly (without the addition of water), or compound (I) may be mixed with an aqueous solution of the solubilizing agent. The solubilizing agent or the aqueous solution of the solubilizing agent may contain various additives. For example, the aqueous solution of the solubilizing agent may be an aqueous solution prepared by dissolving the solubilizing agent in water, a buffer solution, physiological saline, or the like.
[0069] The concentration of the solubilizing agent in the aqueous solution to be mixed with Compound (I) is, for example, 5 wt% or more, preferably 10 wt% or more, and more preferably 20 wt% or more. By dissolving Compound (I) in the presence of such a concentration of solubilizing agent, a concentrated solution in which Compound (I) is dissolved at a high concentration can be obtained. The concentration of the solubilizing agent in the concentrated solution is, for example, 5 wt% or more, preferably 10 wt% or more, and more preferably 20 wt% or more, and is, for example, 99.7 wt% or less, or, for example, 98 wt% or less.
[0070] The concentration of compound (I) in the concentrated solution is, for example, 0.1 mg / g to 300 mg / g, preferably 1 mg / g to 150 mg / g, more preferably 2 mg / g to 50 mg / g.
[0071] The concentrated solution may contain appropriate additives (antioxidants, excipients, pH adjusters, isotonicity agents, etc.) depending on the composition of the target freeze-dried solution. The type and concentration of additives in the concentrated solution may be appropriately set depending on the composition of the target freeze-dried solution. As described above, the additives may be added to the solubilizing agent or an aqueous solution thereof and then mixed with compound (I), or may be added separately when the solubilizing agent or an aqueous solution thereof is mixed with compound (I).
[0072] The concentrated solution preferably contains an antioxidant. The concentration of the antioxidant in the concentrated solution is, for example, 0.1 mg / g to 300 mg / g, preferably 0.5 mg / g to 150 mg / g, and more preferably 1 mg / g to 50 mg / g. When the concentrated solution contains an antioxidant, it is possible to suppress the generation of an oxidized product of compound (I).
[0073] Compound (I) and the solubilizing agent or an aqueous solution thereof can be mixed by stirring, shaking, ultrasonic irradiation, etc. The mixing time can be, for example, 30 minutes to 120 hours, preferably 2 hours to 48 hours. The mixing temperature can be, for example, 0°C to 50°C, preferably 10°C to 30°C.
[0074] C-2. Step II In Step II, the concentrated solution is mixed with a diluent. The diluent contains water and, if necessary, may further contain additives (antioxidants, excipients, pH adjusters, isotonicity agents, etc.). A diluent containing an antioxidant can suppress the generation of oxidized forms of Compound (I). The type and concentration of additives in the diluent can be appropriately set depending on the composition of the desired lyophilized solution. For example, the diluent may be water, a buffer solution, physiological saline, etc. Alternatively, the additives may be added separately when the concentrated solution is mixed with the diluent.
[0075] The concentrated solution and the diluent can be mixed by stirring, shaking, ultrasonic irradiation, etc. The mixing time can be, for example, 10 seconds to 48 hours, preferably 1 minute to 2 hours. The mixing temperature can be, for example, 0°C to 50°C, preferably 10°C to 30°C.
[0076] A freeze-dried solution is obtained by Step II. The concentrations of each component (compound (I), solubilizing agent, antioxidant, excipient, pH adjuster, isotonicity agent, etc.) in the freeze-dried solution are as described in Section B.
[0077] In the method for producing the lyophilized solution, the solubilizing agent or its aqueous solution, concentrated solution, and / or diluent may be deoxygenated. This can suppress the generation of oxidized forms of Compound (I) in the lyophilized solution or a liquid preparation reconstituted from the lyophilized solution. Examples of deoxygenation treatment include nitrogen bubbling and degassing. The treatment conditions are not particularly limited and can be set to any appropriate conditions that can achieve the effects of the present invention.
[0078] D. Method for Producing Freeze-Dried Preparations The freeze-dried preparations described in Section A can be produced by freeze-drying the freeze-dried solution described in Section B. For example, the freeze-dried solution described in Section B is filled into a container such as a vial and pre-frozen, and then subjected to primary drying (sublimation drying) under reduced pressure, followed by secondary drying (removal of bound water). The water content of the resulting freeze-dried preparation is, for example, 8 wt% or less, preferably 5 wt% or less, and more preferably 3 wt% or less. The freeze-drying conditions can be appropriately set depending on the composition, amount, etc. of the freeze-dried solution. The freeze-drying can be performed using a commercially available freeze-dryer. The produced freeze-dried preparation can be sealed in a container such as a vial and supplied. The sealing can be performed, for example, by vacuum sealing or nitrogen-substituted sealing.
[0079] E. Methods of Use and Applications of the Lyophilized Preparation An administration solution can be obtained by reconstituting the lyophilized preparation described in Section A. Reconstitution refers to dissolving the lyophilized preparation in a dissolving solution to prepare it again as a liquid. As described above, the lyophilized preparation has excellent solubility in water, so that an administration solution containing Compound (I) at a practically sufficient concentration can be easily prepared just before use.
[0080] The liquid formulation may be, for example, an injection, a spray, eye drops, a topical solution, etc. In one embodiment, the liquid formulation is an intravitreal injection, which may be injected into the patient's vitreous by injection.
[0081] As the dissolving solution, a pharmaceutically acceptable solvent can be used as appropriate. Specific examples of the dissolving solution include water (water for injection, etc.), physiological saline, and various buffer solutions (phosphate buffer, phosphate-buffered saline, citrate buffer, etc.). The pH of the liquid preparation is, for example, 6 to 8.
[0082] The concentration of Compound (I) in the liquid preparation can be appropriately set depending on the purpose, application, etc. The concentration can be, for example, 3 μg / mL to 60 μg / mL. Furthermore, the concentration can be, for example, 5 μM to 100 μM. The concentration of the solubilizing agent in the liquid preparation can be, for example, 0.01 wt% to 1.5 wt%, preferably 0.02 wt% to 1 wt%.
[0083] The purity of compound (I) in the liquid preparation is, for example, 90% or more, preferably 92% or more, more preferably 95% or more. By preparing compound (I) as a lyophilized preparation, it is possible to suppress the generation of oxidized forms during storage, and as a result, it is possible to easily and quickly prepare a liquid preparation containing compound (I) with high purity in time for administration.
[0084] Since the compound (I) can perform fluorescent imaging of calpain activity, the freeze-dried preparation and liquid preparation can be used for diagnosing diseases associated with calpain activity, determining the suitability or therapeutic effect of calpain inhibitors for such diseases, and the like.
[0085] A disease associated with calpain activity may be a disease whose onset or exacerbation is contributed by the expression or activity of calpain. Examples of diseases associated with calpain activity include retinal diseases or ophthalmic diseases such as glaucoma including normal-tension glaucoma, autosomal dominant neovascular inflammatory vitreoretinopathy, retinitis pigmentosa, age-related macular degeneration, retinal neuropathy or retinal vascular occlusive disease associated with diabetes, retinal ischemia, cataract, normal-tension glaucoma, etc.; muscle diseases such as muscular dystrophy; diabetes; inflammatory diseases or autoimmune diseases such as acute esophagitis, multiple sclerosis, idiopathic inflammatory myopathy, and autoimmune encephalitis; spinal cord injury, Parkinson's disease, Examples of diseases that can be treated include neurological disorders such as neurodegenerative diseases, lissencephaly, Alzheimer's disease, and spinocerebellar degeneration; cardiovascular diseases such as cardiac ischemia-reperfusion injury, chronic heart disease, abdominal aortic aneurysm, and atherosclerosis; cancers such as melanoma, breast cancer, and brain tumors; aging syndromes and progeria; parasitic and pathogenic microbial infections such as malaria, trypanosomiasis, African sleeping sickness, schistosomiasis, leishmaniasis, and sickle cell disease; traumatic brain injury, Machado-Joseph disease; preeclampsia; and pulmonary fibrosis. Among these, application to eye diseases including glaucoma and cancers such as brain tumors is being particularly investigated.
[0086] The present invention will be specifically explained below using examples, but the present invention is not limited to these examples. Unless otherwise specified, each operation was performed at room temperature (about 25°C). HPLC measurements were performed under the following conditions. <HPLC measurement conditions> Column: Meteoric core C8, 5 μm, 4.6 × 150 mm (YMC Co., Ltd.) Column temperature: 25°C Flow rate: 1.0 mL / min Wavelength: 254 nm Mobile phase A: water / TFA (1000:1), mobile phase B: acetonitrile / TFA (1000:1) Mobile phase flow
[0087] [Production Example 1: Synthesis of Compound A] The TFA salt of Compound A shown below was synthesized according to the method described in Patent Document 1. The obtained TFA salt (14.7 mg) was dissolved in 2 mL of dichloromethane, and 1 mL of saturated aqueous sodium bicarbonate solution was added and mixed. The mixture was extracted with dichloromethane, and the organic phase was dried over sodium sulfate. The organic solvent was evaporated under reduced pressure to obtain Compound A (pale pink solid, 9.9 mg, 79%) as a desalted form.
[0088] Test Example 1: Dissolution test of Compound A 1 mg of Compound A was dissolved in 6.55 mM phosphate buffer (pH 7) containing 0 to 0.03 wt % of polysorbate 20 (Fujifilm Wako Pure Chemical Industries, Ltd., hereinafter referred to as "PS20") or NaHCO 3 containing 0 to 0.03 wt % of PS20. 2 P.O. 4 10 mL of the aqueous solution (0.33 mg / mL) was placed in a 20 mL glass vial, and the atmosphere inside the vial was replaced with nitrogen. The vial was placed in an aluminum laminate zip and shaken overnight. The phosphate buffer solution was NaH 2 P.O. 4 and Na 2 HPO 4 The solution was filtered through a PVDF filter (Millex-GV, 0.22 μm, PVDF, 4 mm), and the first 10 drops and the following solutions were collected to obtain solutions of formulations 1 to 8. The resulting solutions were measured by HPLC, and the concentrations of compound A were calculated. The results are shown in the table below and in Figure 1.
[0089]
[0090] Formulations 1 to 4 (phosphate buffer) and formulations 5 to 8 (NaH 2 P.O. 4 In all the solutions, the dissolution concentration of Compound A increased with increasing PS20 concentration. The use of PS20 as a solubilizing agent was effective in increasing the dissolution concentration of Compound A.
[0091] Test Example 2: Method for dissolving Compound A Solutions of Compound A were prepared using the following Methods A to C, and the concentrations of Compound A in the solutions were measured by HPLC. The HPLC measurement samples were prepared by filtering each solution through a PVDF filter (Millex-GV, 0.22 μm, PVDF, 4 mm) and collecting the solution from the first 10 drops onwards (the same applies to the following HPLC measurements). The solution compositions and the measured values of Compound A concentrations are shown in the table below. Method A: Compound A powder was weighed into a glass vial and added to 0.03 wt % or 0.3 wt % PS20 aqueous solutions containing various additives so that the concentrations of Compound A became 11.4 μg / mL or 114 μg / mL, and the mixture was stirred overnight. Thus, solutions of Formulations 9 and 10 were prepared. Method B: 56.3 mg of compound A was weighed into a brown vial, and PS20 was added to adjust the compound A concentration to 36.5 mg / g. A stir bar was placed in the vial, which was then sealed and stirred overnight in the dark to dissolve compound A in PS20. The above solution was weighed into a glass vial, and an aqueous solution containing various additives was added to adjust the compound A concentration to 11.4 μg / mL or 114 μg / mL, followed by mixing with ultrasonic vibration for 1 minute. This prepared solutions of formulations 11 to 13. Method C: Compound A was weighed into a brown vial, and a 20 wt% aqueous solution of PS20 was added to adjust the compound A concentration to 7.30 mg / g. The solution was stirred overnight in the same manner as in Method B to dissolve compound A. The above solution was weighed into a glass vial, and an aqueous solution containing various additives was added to adjust the compound A concentration to 114 μg / mL, followed by mixing with ultrasonic vibration for 1 minute. This prepared a solution of formulation 14.
[0092]
[0093] In Test Example 1, the solubility of Compound A in a 0.03 wt% PS20 solution (phosphate buffer) was 12.4 μg / mL. However, the measured concentrations of Compound A in Formulations 9 and 10 were 0.72 and 9.23 μg / mL, respectively, which were significantly lower than 1 / 10 of the target concentration. In both solutions, residual Compound A powder was visually observed, and dissolving Compound A from the powder state was difficult even after a day. On the other hand, in Formulations 11 to 14, the measured concentrations of Compound A were generally at the target concentration. Furthermore, the PS20 solution of Compound A rapidly dissolved in phosphate buffer, and no residual Compound A was visually observed. Compound A was also soluble in a 20 wt% PS20 aqueous solution, and solutions could be prepared using this solution. Pre-dissolving Compound A in PS20 or a PS20 aqueous solution was effective for preparing solutions at the specified concentration in a short period of time.
[0094] Test Example 3: Study on the stability of freeze-dried preparations of Compound A 1 2 P.O. 4 and Na 2 HPO 4 The above was dissolved in distilled water, and the pH was adjusted appropriately with 2 M hydrochloric acid or 2 M sodium hydroxide aqueous solution to prepare phosphate buffer solutions (2.5 to 250 mM) at pH 7.0. Using the resulting phosphate buffer solutions, solutions of various compositions were prepared according to Method B. Each solution was filled at 1 mL per 10 mL amber vial (Daiwa Special Glass Co., Ltd.), sealed with a laminate-coated rubber stopper (Daikyo Seiko Co., Ltd.), and capped with an aluminum cap to obtain liquid formulations 15 to 19. Each solution used in formulations 15 to 19 was filled at 1 mL per 10 mL amber vial (Daiwa Special Glass Co., Ltd.) as the lyophilized solutions for formulations 20 to 24, respectively. The vials were then frozen at -30°C or below, with a laminate-coated rubber stopper (Daikyo Seiko Co., Ltd.). After reducing the pressure, the vials were heated to -5°C over 4 hours and primarily dried for 36 hours. The vials were heated to 20°C over 2 hours and secondary dried for 2 hours, and then sealed with a rubber stopper while still under vacuum. The tubes were capped with aluminum caps to obtain lyophilized preparations of formulations 20 to 24. The solution compositions of each formulation are shown in the table below. The compound A concentration is an actual value measured by HPLC.
[0095] Formulations 15 to 24 were placed in aluminum laminated zip bags and stored at room temperature and protected from light. The compound A content and purity, the content of the oxidized form (the main degradation product of compound A), and the total content of related substances at the time of preparation and storage of each formulation were determined by HPLC. Test solutions for measuring the purity of the lyophilized formulations were prepared by adding 1 mL of distilled water to the formulation and shaking up and down 10 times. Solutions for measuring the content of the lyophilized formulations were prepared by adding an appropriate amount of distilled water to each vial to achieve a volume of 1 mL. As described above, all solutions were filtered through a PVDF filter (Millex-GV, 0.22 μm, PVDF, 4 mm), and the solution obtained after the first 10 drops was used as the test solution. All lyophilized formulations (formulations 20 to 24) had good solubility in distilled water. They could be dissolved by adding distilled water and shaking up and down 10 times. The time required for dissolution was less than 1 minute. The content and purity of Compound A, the oxidized form content, and the total related substance content at each time point for each formulation are shown in the table below. The content (%) of Compound A was calculated as the ratio to the Compound A concentration in the lyophilized solution on day 0. The purity of Compound A, the oxidized form content, and the total related substance content were calculated by the area normalization method based on the peak areas in the HPLC chromatogram. The same applies to the following test examples.
[0096]
[0097] In the liquid formulations (formulations 15-19), both the content and purity of Compound A at the time of storage (4, 7, and 14 days) were significantly reduced. In particular, a significant increase in the oxidized form, which is the main decomposition product, was observed. In the lyophilized formulations (formulations 20-24), purity loss was suppressed compared to the liquid formulations, and the generation of the oxidized form, which is the main cause of purity loss, was also slow. Furthermore, the content was confirmed to be maintained in Formulation 22. Furthermore, the time required for redissolution of Formulation 22 in water was less than 1 minute. While dissolution of the powdered Compound A in Test Example 1 was difficult, the lyophilized formulation was able to dissolve rapidly. As described above, the lyophilized formulation is effective in stabilizing the content and purity of Compound A and also has excellent resolubility in water.
[0098] The structure of the oxidized form, which was the main decomposition product of Compound A, was confirmed by HPLC / MS analysis, and it was found that the oxidized form had the structure shown below.
[0099] Test Example 4: Study 2 on the stability of lyophilized formulations of Compound A Lyophilized formulations of formulations 25 to 29 were produced in the same manner as in Test Example 3. The composition of the lyophilized solution used to obtain each formulation is shown in the table below. In the table, the concentration of Compound A is an actually measured value.
[0100]
[0101] The lyophilized formulations of formulations 25 to 29 were placed in aluminum laminated zip bags and stored at room temperature in the dark. The purity of Compound A, the content of oxidized forms (the main degradation products of Compound A), and the content of total related substances at the time of preparation and storage of each formulation were calculated by HPLC analysis (area percentage). Test solutions for measuring the purity of the lyophilized formulations were prepared by adding 1 mL of distilled water to the formulation and shaking it upside down 10 times. All formulations except for formulation 27 had good solubility in water. Specifically, formulations 25, 26, 28, and 29 could be dissolved by adding water and shaking it upside down 10 times. The time required for dissolution was less than 1 minute. Formulation 27 could be dissolved within 3 minutes of adding water and shaking it upside down 10 times or more. The purity, oxidized form content, and total related substance content of each formulation at each time point are shown in the table below.
[0102]
[0103] Formulations 25 to 29 contained trehalose as an excipient in the lyophilized solution at concentrations of 50 to 300 mg / mL, and all had the same purity and amount of oxidant produced as formulation 22. In formulations 25, 28, and 29, the weight ratio of PS20 to compound A was 27.0 times, 53.8 times, and 79.7 times, respectively. In all of the lyophilized formulations, oxidant production was milder than in formulations 15 to 19, and it was possible to produce lyophilized formulations with PS20 contents in the same range.
[0104] Test Example 5: Study 3 on the Stability of Lyophilized Preparations of Compound A According to Test Example 3, the decrease in purity of Compound A in the preparation was mainly due to the decomposition of Compound A to its oxidized form. Therefore, in order to suppress the formation of the oxidized form, lyophilized preparations of each formulation were produced as follows. PS20 and a 20 wt% PS20 aqueous solution were bubbled with nitrogen for 20 minutes. Compound A was weighed into a 3 mL brown glass vial, and the above PS20 and 20 wt% PS20 aqueous solutions were added thereto so that the concentrations of Compound A became 36.5 mg / g and 7.30 mg / g, respectively. The vials were sealed and stirred overnight at room temperature in the dark to dissolve Compound A. Phosphate buffer solution that had been bubbled with nitrogen for 20 minutes was added to the above Compound A solution, and the mixture was dissolved by ultrasonic vibration for 1 minute to prepare lyophilized solutions with the compositions shown in the table below. The Compound A concentrations in the table are actual measured values.
[0105]
[0106] Each lyophilized solution was filled in 10 mL amber vials (Daiwa Special Glass Co., Ltd.) at 0.5 mL, and a laminate-coated rubber stopper (Daiko Seiko Co., Ltd.) was placed on top. The vials were frozen at -30°C or below. After reducing the pressure, the vials were heated to -5°C over 4 hours and then subjected to primary drying for 24 hours. The vials were heated to 20°C over 2 hours and subjected to secondary drying for 2 hours. The vials were sealed with rubber stoppers while still under vacuum. The vials were capped with aluminum caps to obtain lyophilized formulations (formulations 30 and 31). Formulations 30 and 31 were placed in aluminum-laminated zip bags and stored at room temperature in the dark. The purity of Compound A, the content of the oxidized form (the main decomposition product of Compound A), and the content of total related substances at the time of preparation and storage of each formulation were calculated by HPLC analysis (area percentage). A test solution for measuring the purity of the lyophilized formulations was prepared by adding 0.5 mL of distilled water and shaking up and down 10 times. All formulations had good solubility in water and could be dissolved by adding water and shaking up and down 10 times. The time required for dissolution was less than 1 minute. The purity, oxidant content, and total related substance content of each formulation at each time point are shown in the table below. In the table, "Lyophilized Solution" represents the lyophilized solution on the day of preparation, while "Day 0" and "Day 15" represent the stability data for the lyophilized formulation on the day of manufacture and 15 days after manufacture, respectively.
[0107]
[0108] Formulations 30 and 31 had lower oxidant contents at the time of preparation of the lyophilized solution compared to formulation 17. Furthermore, the amount of oxidant at the time of preparation of the lyophilized solution and production of the lyophilized formulation was smaller compared to formulations 20 to 29. Preparing and producing the lyophilized solution and lyophilized formulation using PS20 solution, buffer solution, etc. that had been previously nitrogen-bubbled was effective in suppressing oxidant generation.
[0109] Test Example 6: Study 4 on the Stability of Lyophilized Compound A Preparations The effect of adding methionine on the inhibition of oxidants at the time of preparation of the lyophilized solution was evaluated as follows. Methionine was added to a mixed solution of distilled water and PS20 to prepare a 20 wt% PS20 aqueous solution (3, 2, 1, 0.2, 0.1 wt% methionine). Compound A was weighed into a 3 mL brown glass vial, and the 20 wt% PS20 aqueous solution was added so that the compound A concentration was 7.30 mg / g. The vial was sealed and stirred overnight at room temperature in the dark to dissolve compound A. A dissolving solution containing various additives, which had been nitrogen-bubbled for 20 minutes, was added to the compound A solution and mixed with ultrasonic vibration for 1 minute to prepare a lyophilized solution with the composition shown in the table below. The compound A concentrations in the table are actual measured values.
[0110]
[0111] Each lyophilized solution was filled in 1 mL amber vials (Daiwa Special Glass Co., Ltd.), fitted with a laminate-coated rubber stopper (Daiko Seiko Co., Ltd.), and frozen at -35°C or below. After reducing the pressure, the vials were heated to -10°C over 4 hours and subjected to primary drying for 32 hours. The vials were heated to 20°C over 2 hours and subjected to secondary drying for 2 hours, and then sealed with rubber stoppers while still under vacuum. The vials were capped with aluminum caps to obtain lyophilized formulations (formulations 32 to 37). Formulations 32 to 37 were placed in aluminum-laminated zip bags and stored at room temperature in the dark. The purity of Compound A, the content of the oxidized form (the main decomposition product of Compound A), and the content of total related substances at the time of preparation and storage of each formulation were calculated by HPLC analysis (area percentage). Test solutions for measuring the purity of the lyophilized formulations were prepared by adding 1 mL of distilled water and shaking up and down 10 times. All formulations had good solubility in water, dissolving within 1 minute after adding water and shaking upside down 10 times. The purity, oxidant content, and total related substance content of each formulation at each time point are shown in the table below. In the table, "Lyophilized Solution" represents the lyophilized solution on the day of preparation, while "Day 0," "Day 14," and "Day 15" represent the stability data for the lyophilized formulation on the day of manufacture and 14 and 15 days after manufacture, respectively.
[0112]
[0113] Compared with formulations 15 to 19, formulation 32 had a lower oxidant content at the time of preparation of the lyophilized solution, and the addition of methionine was effective in suppressing the generation of oxidants. In formulations 33 to 37, the addition of methionine also suppressed the generation of oxidants at the time of preparation of the lyophilized solution. The amount of oxidant generated depended on the amount of methionine added. In formulations 33 to 37, the weight of methionine added was equivalent to 0.13 to 3.98 times the weight of Compound A.
[0114] Test Example 7: Study on the Stability of Lyophilized Formulations of Compound A (5) The stability of lyophilized formulations containing various excipients was studied. Trehalose, sucrose, or mannitol was used as the excipient. Furthermore, a formulation containing sodium chloride was also studied as an excipient-free formulation. Methionine was added to a mixed solution of distilled water and PS20 to prepare a 20 wt% PS20 aqueous solution (2 wt% methionine). Compound A was weighed into a 3 mL brown glass vial, and the 20 wt% PS20 aqueous solution was added so that the compound A concentration was 7.30 mg / g. The vial was sealed and stirred overnight at room temperature in the dark to dissolve compound A. A dissolving solution containing various additives that had been nitrogen-bubbled for 20 minutes was added to the resulting compound A solution, and the solution was dissolved by ultrasonic vibration for 1 minute to prepare a lyophilized solution with the composition shown in the table below. The compound A concentrations in the table are actual measured values.
[0115] Each lyophilized solution was filled in 1 mL amber vials (Daiwa Special Glass Co., Ltd.), fitted with a laminate-coated rubber stopper (Daiko Seiko Co., Ltd.), and frozen at -35°C or below. After reducing the pressure, the vials were heated to -10°C over 4 hours and subjected to primary drying for 32 hours. The vials were heated to 20°C over 2 hours and subjected to secondary drying for 2 hours, and then sealed with rubber stoppers while still under vacuum. The vials were capped with aluminum caps to obtain lyophilized formulations (formulations 38 to 41). Formulations 38 to 41 were placed in aluminum-laminated zip bags and stored at room temperature in the dark. The purity of Compound A, the content of the oxidized form (the main decomposition product of Compound A), and the content of total related substances at the time of preparation and storage of each formulation were calculated by HPLC analysis (area percentage). A test solution for measuring the purity of the lyophilized formulations was prepared by adding 1 mL of distilled water and shaking up and down 10 times. All formulations had good solubility in water, dissolving within 1 minute after adding water and shaking upside down 10 times. The purity, oxidant content, and total related substance content of each formulation at each time point are shown in the table below. In the table, "Lyophilized Solution" represents the lyophilized solution on the day of preparation, while "Day 0" and "Day 7" represent the stability data for the lyophilized formulation on the day of manufacture and 7 days after manufacture, respectively.
[0116] As shown in the table above, regardless of the type of excipient or whether or not it was added, the generation of oxidants during preparation of the lyophilized solution and storage of the lyophilized formulation was minimal. Various excipients can be used for lyophilized formulations of Compound A, and formulations without added excipients can also be produced.
[0117] Test Example 8: Study on reconstitution of lyophilized formulation of Compound A Physiological saline (physiological saline "Otsuka saline injection") was added to a lyophilized formulation prepared according to the same formulation as Formulation 32 except for the concentration of Compound A in the lyophilized solution, and the solution was dissolved to a volume of 5 mL to obtain a reconstituted solution (liquid) of Compound A. The concentration of Compound A in the reconstituted solution was calculated by HPLC measurement, and the content of Compound A was calculated. The results are shown in the table below. In the table, the content of Compound A is the ratio to the content of Compound A in the lyophilized solution used to produce the lyophilized formulation (measured concentration of Compound A: 149.2 μg / mL).
[0118]
[0119] The lyophilized formulation was dissolved in saline to obtain a reconstituted solution having the desired concentration of Compound A for administration. The content of Compound A in the reconstituted solution was approximately the same as that in the same amount of lyophilized solution used to prepare the lyophilized formulation. The reconstituted solution was clear and did not contain visible particles.
[0120] Test Example 9: Study on the stability and reconstitution of lyophilized formulations of Compound A Lyophilized formulations containing PS40 or PS80 as a solubilizing agent were prepared, and stability and reconstitution were evaluated. Methionine was added to a mixed solution of distilled water and PS40 or PS80 to prepare 20 wt% PS40 and 20 wt% PS80 aqueous solutions (2 wt% methionine). Compound A was weighed into a 3 mL brown glass vial, and the above 20 wt% PS40 aqueous solution or 20 wt% PS80 aqueous solution was added so that the concentration of Compound A was 7.30 mg / g. The vial was sealed and stirred overnight at room temperature in the dark to dissolve Compound A. A dissolving solution containing various additives was added to the obtained Compound A solution, and the solution was dissolved by ultrasonic vibration for 1 minute to prepare lyophilized solutions with the compositions shown in the table below. The Compound A concentrations in the table are actual measured values.
[0121] Each lyophilized solution was filled in 1 mL amber vials (Daiwa Special Glass Co., Ltd.), fitted with a laminate-coated rubber stopper (Daiko Seiko Co., Ltd.), and frozen at -35°C or below. After reducing the pressure, the vials were heated to -10°C over 4 hours and subjected to primary drying for 32 hours. The vials were heated to 20°C over 2 hours and subjected to secondary drying for 2 hours, and then sealed with rubber stoppers while still under vacuum. The vials were capped with aluminum caps to obtain lyophilized formulations (formulations 42 and 43). Formulations 42 and 43 were placed in aluminum-laminated zip bags and stored at room temperature in the dark. The purity of compound A, the content of the oxidized form, which is the main decomposition product of compound A, and the content of total related substances at the time of preparation and storage of each formulation were calculated by HPLC analysis (area percentage). A test solution for measuring the purity of the lyophilized formulations was prepared by adding 1 mL of distilled water and shaking up and down 10 times. All formulations had good solubility in water, dissolving within 1 minute after adding water and shaking upside down 10 times. The purity, oxidant content, and total related substance content of each formulation at each time point are shown in the table below. In the table, "Lyophilized Solution" represents the lyophilized solution on the day of preparation, while "Day 0" and "Day 7" represent the stability data for the lyophilized formulation on the day of manufacture and 7 days after manufacture, respectively.
[0122] As shown in the table above, even when PS40 or PS80 was used as the solubilizing agent, the generation of oxidants during preparation of the lyophilized solution and storage of the lyophilized formulation was minimal. Various solubilizing agents can be used in the lyophilized formulations according to embodiments of the present invention.
[0123] Distilled water was added to Formulations 42 and 43 to dissolve them in 2 mL of solution, thereby obtaining a reconstituted solution (liquid) of Compound A. The concentration of Compound A in the reconstituted solution was calculated by HPLC measurement, and the content of Compound A was calculated. The results are shown in the table below. In the table, the content of Compound A is the ratio to the content of Compound A in the freeze-drying solution used to produce the freeze-dried formulation.
[0124]
[0125] The lyophilized formulations of Formulations 42 and 43 were dissolved in distilled water to obtain reconstituted solutions of Compound A. The content of Compound A in the reconstituted solutions was approximately the same as the content of Compound A in the same amount of lyophilized solution used to prepare the lyophilized formulations. The reconstituted solutions were clear and did not contain visible particles.
[0126] The present invention can be suitably used in the medical field, for example, in the diagnosis of glaucoma, cancer, and the like.
Claims
1. A compound represented by the following general formula (I): [wherein A and B each independently represent the same or different amino acid residues, wherein the bond between A and the NH bonded to A is an amide bond between the C-terminus of A and the NH, A and B are bonded to each other by an amide bond, and the bond between B and the carbonyl (C=O) bonded to B is an amide bond between the N-terminus of B and the carbonyl (C=O); R 1 are the same or different and represent substituents attached to the benzene ring; p represents an integer of 0 to 4; R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 each independently represents a hydrogen atom, a hydroxyl group (OH group), a halogen atom, or an optionally substituted linear, branched, or cyclic alkyl group; R 8 and R 9 each independently represents a hydrogen atom or an optionally substituted linear, branched, or cyclic alkyl group; 8 and R 9 may be bonded to form a ring, or R 3 and R 8 and may be bonded to form a ring, and / or R 4 and R 9 may be bonded to form a ring; X represents a linear or branched C1-C3 alkylene group; R 10 and R 11 each independently represents a hydrogen atom, a hydroxyl group (OH), an alkoxy group, or an optionally substituted linear, branched, or cyclic alkyl group; 10 and R 11 may be bonded to form a ring; 12 represents a hydrogen atom, an optionally substituted linear, branched or cyclic alkyl group, an optionally substituted linear or branched alkenyl group, an optionally substituted linear or branched alkynyl group, an optionally substituted aryl group, or an optionally substituted heterocyclic group, or R 10 Or R 11 and L may be bonded to form a ring; L is an amide bond, an ester bond, or -(linear or branched alkylene-O-) n - (n is an integer of 1 to 10) or a single bond, or a salt thereof.
2. The lyophilized formulation according to claim 1, further comprising a solubilizing agent.
3. The freeze-dried formulation according to claim 2, wherein the solubilizing agent comprises polyoxyethylene sorbitan fatty acid esters and / or polyoxyethylene polyoxypropylene glycol.
4. The freeze-dried preparation according to claim 2, wherein the solubilizing agent is at least one selected from polysorbate 20, polysorbate 40, and polysorbate 80.
5. The freeze-dried preparation according to claim 2, wherein the content of the solubilizing agent is 3 to 300 parts by weight per 1 part by weight of the compound or a salt thereof.
6. The lyophilized formulation of claim 1, further comprising an antioxidant.
7. The lyophilized formulation of claim 6, wherein the antioxidant comprises methionine.
8. The freeze-dried preparation according to claim 6, wherein the content of the antioxidant is 0.01 to 100 parts by weight per 1 part by weight of the compound or a salt thereof.
9. The lyophilized formulation of claim 1, further comprising at least one additive selected from a pH adjusting agent, an excipient, and an isotonicity agent.
10. The freeze-dried preparation according to claim 1, which is a diagnostic agent for glaucoma or cancer.
11. A compound represented by the following general formula (I): [wherein A and B each independently represent the same or different amino acid residues, wherein the bond between A and the NH bonded to A is an amide bond between the C-terminus of A and the NH, A and B are bonded to each other by an amide bond, and the bond between B and the carbonyl (C=O) bonded to B is an amide bond between the N-terminus of B and the carbonyl (C=O); R 1 are the same or different and represent substituents attached to the benzene ring; p represents an integer of 0 to 4; R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 each independently represents a hydrogen atom, a hydroxyl group (OH group), a halogen atom, or an optionally substituted linear, branched, or cyclic alkyl group; R 8 and R 9 each independently represents a hydrogen atom or an optionally substituted linear, branched, or cyclic alkyl group; 8 and R 9 may be bonded to form a ring, or R 3 and R 8 and may be bonded to form a ring, and / or R 4 and R 9 may be bonded to form a ring; X represents a linear or branched C1-C3 alkylene group; R 10 and R 11 each independently represents a hydrogen atom, a hydroxyl group (OH), an alkoxy group, or an optionally substituted linear, branched, or cyclic alkyl group; 10 and R 11 may be bonded to form a ring; 12 represents a hydrogen atom, an optionally substituted linear, branched or cyclic alkyl group, an optionally substituted linear or branched alkenyl group, an optionally substituted linear or branched alkynyl group, an optionally substituted aryl group, or an optionally substituted heterocyclic group, or R 10 Or R 11 and L may be bonded to form a ring; L is an amide bond, an ester bond, or -(linear or branched alkylene-O-) n - (n is an integer of 1 to 10) or a single bond] or a salt thereof, a solubilizing agent, and water.
12. The freeze-drying solution according to claim 11, wherein the solubilizing agent comprises polyoxyethylene sorbitan fatty acid esters and / or polyoxyethylene polyoxypropylene glycol.
13. The freeze-dried solution according to claim 12, wherein the solubilizing agent is at least one selected from polysorbate 20, polysorbate 40, and polysorbate 80.
14. The lyophilization solution of claim 11, further comprising an antioxidant.
15. The lyophilization solution of claim 14, wherein the antioxidant comprises methionine.
16. The lyophilized solution according to claim 11, wherein the concentration of the compound or its salt is 6 μM or more.
17. The lyophilization solution of claim 11, further comprising at least one additive selected from a pH adjusting agent, an excipient, and a tonicity agent.
18. A method for producing the freeze-dried solution according to claim 11, comprising: mixing the compound or a salt thereof with a solubilizing agent or an aqueous solution thereof to prepare a concentrated solution; and mixing the concentrated solution with a diluent.
19. The method for producing a freeze-dried solution according to claim 18, wherein the concentration of the solubilizing agent in the concentrated solution is 5 wt % or more.
20. The method of producing a freeze-dried solution according to claim 18, wherein the concentrated solution and / or the diluent comprises an antioxidant.
21. The method for producing a freeze-dried solution according to claim 18, further comprising deoxygenating the solubilizing agent or its aqueous solution, the concentrated solution, and / or the diluent.
22. A method for producing a freeze-dried preparation, comprising freeze-drying the freeze-dried solution according to any one of claims 11 to 17.
23. A liquid preparation obtained by reconstituting a lyophilized formulation according to any one of claims 1 to 10.
Citation Information
Patent Citations
Methods for detecting calpain-3 activity in biological samples and peptides for performing said methods
JP2004520850A
Enzyme-sensitive ligation in vivo polynucleotide delivery conjugate
JP2014505685A
Pharmaceutical composition containing PEGylated anti-human NGF antibody Fab' fragment
JP2022023223A
Fluorescent probes
WO2022270607A1
